current
time
field
vaccinolog
remain
empir
mani
respect
vaccin
develop
vaccin
immunogen
vaccin
efficaci
part
histor
driven
empir
isolateinactivateinject
paradigm
turn
populationlevel
public
health
paradigm
dose
everyon
everi
diseas
model
norm
think
regard
prevent
vaccineprevent
infecti
diseas
addit
recent
vaccin
design
specif
overcom
immunosenesc
age
consist
postwwii
mental
develop
vaccin
vaccin
program
children
recogn
current
lack
knowledg
concern
immun
respons
vaccin
gener
critic
barrier
understand
poor
vaccin
respons
elderli
immunoimmatur
discoveri
new
correl
vaccin
immunogen
vaccin
respons
biomark
direct
approach
new
vaccin
develop
new
field
vaccinom
adversom
provid
model
permit
global
profil
innat
humor
cellular
immun
respons
integr
system
biolog
level
advanc
scienc
beyond
reductionist
scientif
approach
reveal
novel
interact
within
immun
system
biolog
system
beyond
transcript
level
critic
develop
downstream
adapt
humor
cellular
respons
infecti
pathogen
vaccin
other
appli
system
level
approach
studi
antibodi
respons
aka
system
serolog
highdimension
cell
subset
immunophenotyp
cytof
vaccin
induc
metabol
chang
turn
knowledg
util
better
understand
follow
identifi
risk
infect
level
risk
exist
regard
poor
immunogen
andor
seriou
advers
event
type
dose
vaccin
need
fulli
protect
individu
toto
approach
allow
person
approach
practic
vaccinolog
analog
substanti
inroad
individu
medicin
play
field
human
health
medicin
herein
briefli
review
field
vaccinom
adversom
person
vaccinolog
vaccin
one
effect
public
health
strategi
prevent
infecti
diseas
decad
ago
describ
idea
vaccinom
adversom
base
immun
respons
network
theori
util
immunogeneticsimunogenom
system
biolog
approach
understand
basi
interindividu
variat
vaccineinduc
immun
respons
human
well
basi
advers
side
effect
vaccin
vaccinom
adversom
explor
influenc
genet
nongenet
regul
heterogen
vaccineinduc
immun
respons
person
popul
level
particular
vaccinom
adversom
util
highthroughput
highdimension
system
biolog
approach
aim
predict
variat
protect
maladapt
innat
adapt
immun
respons
vaccin
regard
basi
person
predict
vaccinolog
assess
individu
genet
background
sex
well
factor
may
impact
vaccin
immunogen
efficaci
safeti
other
wide
publish
applic
tool
concept
vaccinom
includ
immunogenet
immunogenom
knowledgebas
direct
develop
new
improv
vaccin
candid
applic
concept
like
allow
explan
quantif
predict
vaccineinduc
protect
immun
responsesinclud
http
elsevi
ltd
right
reserv
develop
predict
immun
signatur
respons
vaccin
inde
previous
publish
believ
first
draft
mathemat
model
predict
equat
describ
nonrandom
event
lead
predetermin
immun
respons
b
x
measur
immun
respons
b
intercept
b
coeffici
ith
variabl
x
indic
amount
chang
unit
chang
x
random
deviat
model
recogn
equat
given
current
state
scienc
incomplet
yet
predict
immun
respons
present
earli
direct
attempt
quantifi
equat
approach
begin
move
us
model
direct
vaccin
develop
advanc
understand
mechan
vaccin
vaccin
adjuv
trigger
use
maladapt
innat
adapt
immun
respons
believ
vaccinom
adversom
repres
approach
counter
standard
method
vaccin
develop
recent
histor
vaccin
develop
empir
despit
mani
emerg
reemerg
complex
hypervari
pathogensmani
elabor
immun
escap
mechan
addit
vaccin
coverag
rate
continu
suffer
societi
riskavers
toward
vaccin
demand
level
safeti
may
achiev
final
onesizefitsal
approach
practic
vaccinolog
ignor
complex
divers
human
immun
system
host
genom
thu
promis
vaccinom
relat
paradigm
identifi
specif
immun
respons
profil
immunosignatur
biomark
predict
vaccin
safeti
andor
efficaci
may
lead
new
vaccin
candid
vaccinom
provid
opportun
examin
immun
respons
gene
like
involv
vaccin
respons
also
possibl
identifi
influenc
new
uncharacter
gene
vaccineinduc
immun
turn
identif
direct
studi
genet
variant
allow
recognit
often
molecular
level
effect
differenti
bind
process
expressionpresent
antigen
viral
peptid
use
vaccin
develop
identif
differenti
rang
present
peptid
genet
restrict
alter
secret
pattern
cytokin
respons
vaccin
vaccin
adjuv
alter
transcript
import
gene
signal
molecul
gene
product
alter
bind
virusantigen
membranebas
receptor
tlr
differenti
receptor
function
express
affin
impact
epigenet
vaccineinduc
immun
respons
util
knowledg
laboratori
creat
researchori
paradigm
discovervalidatecharacterizeappli
may
use
new
candid
vaccin
develop
fig
paradigm
abl
util
vaccinom
approach
discov
genet
variant
significantli
associ
subsequ
downstream
immun
respons
valid
variant
inde
associ
seek
character
mechan
wherebi
effect
occur
final
appli
knowledgeoften
function
studi
confirm
effect
immun
knowledg
exploit
develop
immun
strategi
enhanc
circumv
genet
restrict
exampl
trigger
vaccineassoci
immun
respons
revers
engin
around
given
genet
obstacl
gener
protect
immun
respons
grow
number
studi
report
unbias
genomewid
assess
genet
variat
influenc
adapt
humor
cellular
vaccineinduc
immun
respons
across
multipl
viral
bacteri
vaccin
exampl
candid
gwa
immunogenet
phamacogenet
studi
identifi
polymorph
hla
kir
mica
btn
gene
associ
immun
respons
pathogen
caus
diseas
human
hepat
c
mycobacterium
lepra
human
immunodefici
viru
measl
similar
studi
identifi
novel
gene
impact
immun
respons
vaccin
includ
hepat
b
rubella
influenza
smallpox
anthrax
mump
gene
associ
studi
measlesmumpsrubella
mmr
vaccin
demonstr
interindividu
variat
measl
vaccin
virusinduc
humor
cellular
respons
significantli
associ
polymorph
immun
respons
gene
togeth
hla
allel
explain
interindividu
variabl
humor
respons
find
illustr
import
key
hla
allel
adapt
humor
immun
respons
measl
vaccin
led
identif
natur
process
present
measlesderiv
peptid
isol
specif
hla
polymorph
associ
vaccin
nonand
hyperrespons
peptid
contain
specif
compon
adjuv
biodegrad
nanoparticl
util
reverseengin
strategi
develop
peptidebas
candid
measl
vaccin
likewis
homan
et
al
attribut
diminish
protect
differenti
hla
present
b
cell
epitop
vaccin
wild
type
strain
mump
viru
diminish
efficaci
could
theoret
overcom
incorpor
defin
critic
immunogen
peptid
improv
vaccin
tlr
gene
repres
import
link
innat
adapt
immun
system
exampl
demonstr
measl
vaccineinduc
humor
respons
significantli
associ
code
polymorph
gene
rubella
vaccin
gene
gene
snp
associ
rubellaspecif
gmcsf
product
recent
mump
vaccin
studi
identifi
replic
snp
associ
decreas
antibodi
titer
snp
associ
increas
cell
respons
unpublish
data
data
strongli
suggest
robust
tlr
activ
measl
mump
rubella
virus
crucial
optim
vaccin
respons
support
find
studi
demonstr
inactiv
mump
vaccin
contain
protollinbas
adjuv
highli
immunogen
mous
model
led
superior
total
igg
level
higher
neutral
antibodi
titer
greater
mucos
iga
product
enhanc
cytokin
secret
one
potenti
applic
find
identifi
specif
critic
interact
tlr
gene
viru
lead
advanc
knowledg
precis
mechan
drive
immun
mmr
vaccin
signific
sex
differ
humor
cellular
immun
respons
vaccin
appar
addit
local
system
advers
rate
gener
higher
femal
versu
male
protect
antibodi
respons
significantli
higher
femal
male
vaccin
influenza
yellow
fever
measl
mump
rubella
hepat
b
herp
simplex
hsv
rabi
smallpox
dengu
virus
sexbas
differ
humor
immun
respons
observ
variou
age
group
suggest
sex
steroid
hormon
singular
mediat
sex
differ
humor
immun
respons
vaccin
suggest
genet
factor
may
import
driver
sexrel
differ
humor
immun
respons
despit
signific
evid
immun
respons
differ
sex
part
vaccin
studi
examin
analyz
immun
respons
outcom
sex
fact
littl
inform
known
potenti
mechan
sexbas
effect
prioriti
vaccin
research
studi
discoveri
specif
factor
involv
sexbas
differ
immun
respons
may
allow
identif
new
correl
vaccin
immunogen
cohort
older
age
younger
age
previous
vaccin
individu
season
trival
influenza
vaccin
induc
higher
hai
antibodi
titer
women
men
across
age
group
similarli
studi
standard
season
influenza
vaccin
highdos
influenza
vaccin
respons
sexbalanc
cohort
elderli
subject
age
demonstr
significantli
higher
rate
seroconvers
femal
male
howev
signific
differ
antibodi
measur
found
male
femal
season
influenza
vaccin
anoth
cohort
older
adult
age
studi
furman
et
al
examin
gene
express
serum
cytokin
chemokin
cell
subset
phosphoryl
event
found
sever
serum
marker
lept
crp
gmcsf
highli
express
femal
male
influenza
vaccin
report
use
system
biolog
approach
identifi
gene
cluster
involv
lipid
biosynthesi
regul
testosteron
significantli
correl
poor
humor
respons
follow
influenza
vaccin
men
data
suggest
gene
cluster
eg
gene
involv
lipid
metabol
could
import
driver
sexrel
differ
humor
immun
respons
collect
knowledg
could
substanti
assist
futur
person
vaccin
develop
effort
gener
new
knowledg
identif
target
biomark
predict
vaccin
respons
specif
popul
eg
femal
vs
male
young
vs
old
obes
vs
lean
research
need
clarifi
effect
sex
immun
respons
identif
molecular
immun
signatur
sex
differ
innat
adapt
immun
respons
vaccin
may
provid
evid
necessari
addit
effort
design
person
vaccin
vaccinom
approach
ie
male
femal
might
vaccin
differ
use
differ
dose
differ
vaccin
provid
equal
protect
reduc
side
effect
signific
global
public
health
issu
age
popul
individu
age
immunosenesc
develop
lead
poorer
immun
respons
vaccin
immunosenesc
agerel
dysregul
immun
system
due
ageassoci
chang
innat
adapt
immun
system
compon
lead
impair
immun
protect
follow
immun
infect
publish
data
reveal
innat
adapt
immun
decreas
age
systemslevel
mechan
find
unclear
particularli
regard
influenza
viral
vaccin
respons
morbid
mortal
associ
healthcar
cost
greater
older
individu
major
sign
innat
immun
dysfunct
commonli
observ
elderli
includ
limit
alter
cytokin
secret
decreas
nk
cell
activ
reduc
tlr
express
chronic
inflammatori
state
elev
level
tnfa
serum
known
inflammag
agerel
humor
immun
dysfunct
exampl
might
overcom
optim
stimul
innat
andor
th
cellspecif
gene
may
differ
male
femal
exampl
adjuv
zoster
subunit
vaccin
hzsu
reduc
risk
herp
zoster
postherpet
neuralgia
immunocompet
person
year
age
older
hzsu
vaccin
contain
varicella
zoster
viru
glycoprotein
e
novel
b
adjuv
system
aim
improv
preserv
age
zosterspecif
cell
respons
agonist
glase
glucopyranosyl
lipid
adjuv
formul
stabl
emuls
shown
enhanc
respons
influenza
vaccin
older
adult
suggest
potenti
mechan
target
innat
receptor
agonist
eg
tlr
enhanc
innat
immun
respons
influenza
given
substanti
diminish
efficaci
influenza
vaccin
age
import
develop
improv
vaccin
data
vaccinom
studi
could
use
inform
direct
ration
develop
nextgener
influenza
vaccinespotenti
circumv
immunosenescencerel
factor
system
biolog
approach
provid
uniqu
opportun
identifi
biomark
like
involv
immun
respons
vaccin
fourati
et
al
appli
system
vaccinolog
approach
examin
gene
signatur
molecular
pathway
agerel
hyporespons
hepat
b
vaccin
hbv
older
adult
observ
b
cell
signal
pathway
higher
memori
b
cell
frequenc
inflammatori
pathway
increas
frequenc
activ
proinflammatori
innat
cell
strongli
correl
higher
low
antibodi
respons
hbv
respect
signatur
includ
serum
cytokin
profil
flow
cytometr
correl
respons
predict
antibodi
respons
hbv
accuraci
studi
demonstr
system
biolog
approach
use
predict
agerel
immun
respons
vaccin
obes
anoth
major
public
global
health
concern
us
adult
nearli
children
adolesc
overweight
obes
weight
gain
across
countri
demonstr
associ
increas
socioeconom
statu
obes
shown
predictor
impair
immunogen
eg
decreas
antibodi
respons
hepat
b
tetanu
toxoid
rabi
influenza
vaccin
consid
marker
state
immunosuppress
extrem
data
suggest
obes
correl
poorer
vaccineinduc
immun
respons
human
research
requir
understand
immun
mechan
alter
obes
individu
age
circul
leptin
level
rise
concomit
reduct
leptin
signal
result
leptin
resist
find
associ
obes
leptin
resist
shown
advers
affect
immun
respons
obes
subject
includ
respons
influenza
viru
exampl
obes
individu
demonstr
decreas
activ
influenzaspecif
cell
compar
healthyweight
person
includ
decreas
product
ifnc
granzym
b
suggest
influenza
vaccin
may
effect
obes
popul
healthyweight
individu
given
moder
seroprotect
influenza
vaccin
obes
older
adult
import
develop
improv
influenza
vaccin
system
biolog
studi
design
identifi
mechan
improv
immun
respons
need
fact
data
vaccin
studi
could
use
inform
direct
ration
develop
person
vaccin
optim
stimul
innat
adapt
immun
respons
male
femal
overcom
immun
defici
induc
obes
care
vaccin
studi
compar
lean
obes
person
could
provid
foundat
data
use
improv
vaccineinduc
protect
obes
subpopul
elev
risk
seriou
vaccineprevent
ill
suboptim
vaccineinduc
protect
respons
adversom
util
toolsmuch
like
use
vaccinomicsto
identifi
character
predict
advers
maladapt
immun
respons
vaccin
promis
adversom
would
develop
identifi
either
predictor
immun
signatur
maladapt
immun
respons
lead
harm
rather
benefit
better
understand
gener
mechan
maladapt
immun
respons
ask
question
scientist
make
sens
centuri
give
vaccin
dose
frequenc
everyon
regardless
age
weight
gender
race
genotyp
medic
condit
exampl
give
adult
male
femal
dose
number
dose
vaccin
ignor
find
femal
nearli
alway
superior
humor
immun
respons
male
vaccin
studi
yet
experi
significantli
side
effectsmor
advers
event
greater
durat
higher
intens
field
young
implement
research
alreadi
reveal
associ
specif
gene
snp
advers
immun
outcom
exampl
associ
cytokin
gene
express
fever
smallpox
vaccin
identifi
studi
demonstr
correl
smallpox
vaccineinduc
fever
snp
smallpox
vaccineinduc
advers
event
fever
rash
enlarg
lymph
node
significantli
associ
mthfr
snp
haplotyp
smallpox
vaccin
use
gener
popul
studi
stand
exampl
use
vaccinom
approach
final
recent
studi
identifi
gener
fever
gene
network
tnfa
vaccin
administr
relationship
mmr
vaccin
administr
snp
gene
despit
tremend
success
vaccin
vaccinologist
face
sever
current
challeng
includ
difficulti
develop
vaccin
hypervari
virus
hiv
rhinoviru
hepat
c
viru
coronaviru
complex
pathogen
malaria
mycobacterium
tuberculosi
newli
emerg
pathogen
zika
viru
zikv
complic
impos
age
immunosenesc
popul
inadequ
understand
neonat
newborn
immun
system
increasingli
immun
defici
immunocompromis
popul
due
hiv
cancer
medic
sexbas
differ
vaccin
respons
adverseev
rate
enhanc
scrutini
vaccin
safeti
note
global
increas
age
weight
addit
vocal
activ
antivaccin
group
whose
messag
easili
counter
fact
scientif
studi
materi
detriment
affect
vaccin
coverag
rate
vaccinom
approach
util
better
understand
issu
inform
use
inform
new
approach
new
understand
new
vaccin
candid
new
technolog
creat
excit
new
opportun
person
medicin
brought
novel
challeng
addit
mention
order
full
potenti
person
vaccin
achiev
must
overcom
addit
challeng
need
follow
larger
genotyp
phenotyp
dataset
often
mani
thousand
ten
thousand
integr
increasingli
divers
highthroughput
highdimension
data
type
biomark
reliabl
distinguish
product
patient
receiv
base
likelihood
respons
advers
side
effect
vaccin
differ
mechan
action
may
requir
move
away
humor
correl
protect
licensur
regard
correl
protect
base
cellular
immun
outcom
like
play
import
role
futur
vaccin
sophist
biostatist
bioinformat
approach
identifi
pattern
caus
network
within
terabyt
level
extrem
high
dimension
data
type
econom
side
method
technolog
transfer
fund
mechan
move
novel
vaccin
develop
vaccinom
approach
low
middleincom
countri
often
need
specif
vaccin
malaria
other
seen
shift
vaccinolog
empir
isolateinactivateinject
paradigm
vaccinolog
use
recombin
technolog
novel
adjuv
howev
even
paradigm
limit
incomplet
mechanist
understand
adjuv
innat
immun
adopt
approach
list
envis
movement
field
era
vaccinolog
expect
see
use
vaccinom
systemslevel
approach
develop
new
vaccin
innov
vaccineantigen
packag
method
adjuv
develop
target
innat
respons
pathway
best
suit
given
pathogen
common
reaction
paradigm
person
vaccinolog
question
cost
econom
one
level
consider
simpli
soon
develop
scienc
effect
answer
howev
like
progress
made
individu
medicin
like
abl
provid
right
vaccin
right
patientfor
right
reason
right
dosewil
lead
improv
medic
outcom
reduc
cost
popul
level
person
vaccinolog
goal
appli
concept
person
medicin
vaccin
rapid
stride
omic
technolog
foundat
work
appli
system
biolog
comput
immunolog
revers
vaccinolog
facilit
modern
approach
vaccin
design
develop
enabl
us
creat
vaccin
formul
new
reemerg
pathogen
eggbas
influenza
vaccin
take
month
creat
recent
licensur
cell
culturebas
influenza
vaccin
demonstr
rapid
scalabl
process
implement
order
creat
vaccin
emerg
influenza
strain
eg
within
week
safe
administ
individu
egg
allergi
ebola
outbreak
liberia
sierra
leon
guinea
provid
exampl
need
rapidli
develop
vaccin
candid
dna
vaccin
viruslik
particl
vaccin
replicatingnonrepl
viral
vector
vaccin
creat
test
among
promis
replicationcompet
recombin
vesicular
stomat
viru
vector
express
glycoprotein
ebola
zair
rvsvzebov
varieti
adenovirusvector
vaccin
express
ebola
glycoprotein
modifi
vaccinia
viru
ankarabas
vaccin
encod
ebola
zair
glycoprotein
mvabnfilo
dnabas
vaccineson
express
glycoprotein
zair
sudan
express
marburg
glycoprotein
although
rvsvbase
vaccin
elicit
high
titer
neutral
ab
contraind
children
compromis
immun
system
viral
vector
vaccin
present
problem
develop
robust
immun
vector
well
target
immunogen
limit
use
singl
vaccin
avail
vaccin
multipl
vector
backbon
open
possibl
primeboost
vaccin
strategi
ebola
similar
appli
hiv
malaria
tuberculosi
regard
primeboost
regimen
use
mvabas
vaccin
booster
vaccin
shown
consider
promis
anoth
exampl
modern
vaccin
develop
appli
new
pathogen
seen
respons
zika
viru
purifi
formalininactiv
vaccin
zikv
piv
develop
walter
reed
armi
institut
research
wrair
evalu
sever
clinic
trial
inactiv
vaccin
preclin
develop
two
variant
plasmid
dna
vaccin
contain
prmenv
protein
develop
niaid
one
formul
current
phase
clinic
trial
inovio
pharmaceut
develop
plasmid
dna
vaccin
also
express
prmenv
current
two
clinic
trial
rnabas
vaccin
varieti
subunit
viral
vectorbas
vaccin
also
develop
dna
rnabas
vaccin
rapidli
made
minim
cost
compar
formul
fairli
stabl
without
coldchain
requir
live
virusbas
vaccin
subunit
vaccin
typic
safer
whole
virusbas
product
repres
activ
area
investig
pathogen
exist
vaccin
also
improv
establish
vaccin
group
other
identifi
pathogenderiv
epitop
preliminari
step
develop
safe
stabl
effect
peptideand
proteinbas
vaccin
smallpox
influenza
measl
tuberculosi
staphylococcu
myriad
viral
bacteri
pathogen
parallel
effort
differ
group
creat
new
vaccin
result
spectrum
potenti
product
uniqu
tailor
specif
popul
group
live
viral
vaccin
rapidli
induc
robust
immun
use
healthi
individu
time
essenc
eg
outbreak
scenario
inactiv
subunit
vaccin
use
vulner
popul
pregnant
women
immunocompromis
condit
young
children
presenc
matern
antibodi
interfer
whole
viru
vaccin
vaccin
base
differ
viral
vector
backbon
combin
effect
primeboost
regimen
vaccin
specif
adjuv
may
appropri
elderli
order
overcom
immunosenesc
young
order
compens
immun
system
immatur
along
increas
number
scientist
believ
person
vaccinolog
revolution
practic
vaccinolog
benefit
human
health
part
develop
field
scienc
vaccinom
adversom
allow
us
develop
molecular
immun
signatur
adapt
maladapt
immun
respons
vaccin
develop
earli
biomark
vaccin
respons
vaccin
trial
identifi
get
vaccin
dose
increas
safeti
public
confid
vaccin
reduc
likelihood
seriou
advers
event
relat
vaccin
mani
way
howev
person
vaccinolog
challeng
difficulti
move
field
away
postwwii
populationlevel
paradigm
one
dose
everi
vaccin
everyon
toward
individu
person
approach
base
uniqu
factor
relev
given
individu
book
structur
scientif
revolut
thoma
kuhn
recogn
wrongli
believ
scientif
progress
process
linear
accret
knowledg
scienc
predic
belief
scientif
commun
understand
world
like
suppress
resist
fundament
novelti
seen
subvers
firmli
held
belief
world
like
later
book
suggest
new
advanc
alway
alway
reveal
scienc
medicin
includ
bodi
belief
incompat
belief
hold
today
advanc
come
reject
timehonor
scientif
theori
favor
anoth
incompat
cognit
bias
opinion
manifest
discuss
scientif
colleagu
develop
field
scienc
schopenhaur
german
philosoph
suggest
new
discoveri
first
ridicul
oppos
final
accept
selfevid
vaccinom
adversom
appear
move
ridicul
oppos
step
notyet
quit
selfevid
phase
continuum
part
challeng
often
concept
person
vaccinolog
suggest
reader
uniqu
vaccin
develop
individu
one
tactic
use
cancervaccin
field
neither
necessari
practic
prevent
infecti
diseas
rather
person
vaccinolog
approach
would
suggest
develop
specif
vaccin
base
factor
relat
overcom
potenti
poor
immunogen
potenti
advers
event
excel
exampl
influenza
vaccin
mere
decad
ago
trival
inject
influenza
vaccin
avail
quadrival
vaccin
unavail
one
except
everyon
receiv
vaccin
dose
regardless
age
weight
immunosuppress
state
etc
current
time
us
multipl
influenza
vaccin
avail
right
vaccin
right
patient
given
right
time
exampl
laiv
live
attenu
influenza
vaccin
use
younger
subject
needlephob
highdos
vaccin
chosen
elderli
recombin
vaccin
chosen
egg
allergi
approach
taken
vaccin
case
may
mean
mere
adjust
dose
base
weight
gender
age
case
may
mean
util
adjuv
nonadjuv
vaccin
base
immun
statu
exampl
includ
recent
licens
adjuv
influenza
vaccin
fluad
demonstr
higher
immunogen
efficaci
nonadjuv
counterpart
highli
effect
zoster
glycoprotein
e
vaccin
contain
live
viru
may
broadli
suitabl
administr
older
individu
thu
movement
toward
new
paradigm
vaccin
practic
base
person
approach
occur
centuri
base
new
scientif
knowledg
market
demand
safeti
consider
immunogen
concern
public
health
trend
age
obes
simultan
pull
individu
medicin
medic
arena
net
result
like
higher
vaccin
coverag
rate
increas
public
confid
vaccin
improv
immunogen
advers
event
rate
reduct
elimin
morbid
mortal
relat
vaccineprevent
diseas
result
anticip
new
era
person
predict
vaccinolog
wherebi
abandon
one
size
dose
fit
vaccin
approach
order
design
develop
new
vaccin
acquir
abil
make
follow
predict
individu
whether
give
vaccin
base
likelihood
respons
perhap
need
likelihood
signific
advers
event
vaccin
number
dose
like
need
induc
protect
respons
vaccin
current
vaccin
develop
larg
empir
vaccin
test
trial
error
mass
produc
given
entir
popul
use
antigen
dose
rout
administr
number
vaccin
age
contrast
new
vaccinedevelop
paradigm
begin
discoveri
new
knowledg
integr
unbias
comprehens
analysi
genom
transcriptom
proteom
metabolom
microbiom
immunomealong
assess
multipl
measur
immun
functionin
order
understand
evalu
perturb
immun
system
find
valid
replic
cohort
addit
model
system
new
knowledg
appli
creation
new
vaccin
formul
undergo
addit
test
start
new
round
discoveri
move
clinic
trial
order
develop
vaccin
product
engin
elicit
avoid
specif
effect
immun
system
product
tailor
specif
subgroup
robust
protect
immun
elicit
old
young
lean
obes
male
femal
avoid
inappropri
immun
respons
due
genet
metabol
race
gender
malnutrit
immunosuppress
host
factor
underli
condit
contract
content
sole
respons
author
necessarili
repres
offici
view
nation
institut
health
author
would
like
acknowledg
contribut
center
diseas
control
prevent
cdc
provid
financi
support
world
health
organ
initi
vaccin
research
dr
poland
chair
safeti
evalu
committe
novel
investig
vaccin
trial
conduct
merck
research
laboratori
dr
poland
offer
consult
advic
vaccin
develop
merck
co
inc
avianax
dynavax
novarti
vaccin
therapeut
emerg
biosolut
adjuv
seqiru
protein
scienc
dr
poland
ovsyannikova
hold
three
patent
relat
vaccinia
measl
peptid
research
dr
kennedi
receiv
fund
merck
research
laboratori
studi
wane
immun
mump
vaccin
activ
review
mayo
clinic
conflict
interest
review
board
conduct
complianc
mayo
clinic
conflict
interest
polici
